Milestone Pharma: Phase 3 RAPID PSVT trial reaches 180 events; topline data on track for mid-H2 2022

Milestone Pharmaceuticals Inc.

Q2 2022 operating loss $16.8M vs income $0.7M prior year due to $15M one-time revenue from Ji Xing in 2021; cash $86.2M.
RAPID Phase 3 PSVT trial achieved target of 180 confirmed events; topline data expected mid-second half 2022.
Ji Xing enrolled first patient in Phase 3 etripamil study in China; data may support NDA in China.
NODE-302 open-label extension data showed 60.2% PSVT conversion at 30 min; 8.5% ED intervention rate.
R&D expense $10.7M in Q2 2022, up from $9.4M due to RAPID trial advancement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.